Actively Recruiting
Effectiveness and Safety of DTI-Guided Minimally Invasive Hematoma Removal Compared to Best Medical Treatment for Acute Basal Ganglia Intracerebral Hemorrhage in Adults
Led by Zhongming Qiu · Updated on 2023-09-13
100
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of diffusion tensor imaging DTI-guided minimally invasive hematoma evacuation compared to best medical therapy in patients with acute spontaneous intracerebral hemorrhage ICH, a severe type of stroke with high early death rates and poor neurological outcomes. This multicenter randomized controlled trial also includes a concurrent observational study for patients who decline randomization but consent to follow-up. The primary outcome is assessed by a blinded evaluator to ensure objective measurement. Participants are randomly assigned to receive either the procedure of minimally invasive hematoma evacuation plus best medical therapy or best medical therapy alone. The trial focuses on patients with bleeding in the basal ganglia diagnosed by CT, with specific bleeding volumes and displacement criteria. The study tracks outcomes at 180 days after randomization, comparing recovery using the modified Rankin scale. During the study, participants undergo assessments including CT and MRI imaging, neurological scoring, and muscle strength evaluation. Follow-ups occur up to 180 days post-treatment to measure functional outcomes and safety. The trial runs from August 2023 to August 2027, with continuous monitoring of participant progress and collection of relevant clinical data.
CONDITIONS
Brief Title
DTI-guided Minimally Invasive Hematoma Evacuation for Intracerebral Hemorrhage
Research Team
Z
Zhongming Qiu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here